170 related articles for article (PubMed ID: 35289201)
1. A Retrospective Study of Intrathecal Pemetrexed Combined With Systemic Therapy for Leptomeningeal Metastasis of Lung Cancer.
Geng D; Guo Q; Huang S; Zhang H; Guo S; Li X
Technol Cancer Res Treat; 2022; 21():15330338221078429. PubMed ID: 35289201
[No Abstract] [Full Text] [Related]
2. Intrathecal chemotherapy combined with systemic therapy in patients with refractory leptomeningeal metastasis of non-small cell lung cancer: a retrospective study.
Zhou T; Zhu S; Xiong Q; Gan J; Wei J; Cai J; Liu A
BMC Cancer; 2023 Apr; 23(1):333. PubMed ID: 37041504
[TBL] [Abstract][Full Text] [Related]
3. Multiple combination therapy based on intrathecal pemetrexed in non-small cell lung cancer patients with refractory leptomeningeal metastasis.
Miao Q; Zheng X; Zhang L; Jiang K; Wu B; Lin G
Ann Palliat Med; 2020 Nov; 9(6):4233-4245. PubMed ID: 33302683
[TBL] [Abstract][Full Text] [Related]
4. [Clinical trials on intrathecal pemetrexed treated leptomeningeal metastases from solid tumors].
Pan ZY; Song YY; Jiang TC; Yang X; Yang GZ
Zhonghua Zhong Liu Za Zhi; 2022 Jan; 44(1):112-119. PubMed ID: 35073657
[No Abstract] [Full Text] [Related]
5. Effects of intrathecal pemetrexed on the survival of patients with leptomeningeal metastasis from lung adenocarcinoma: a propensity score matching analysis.
Hong Y; Miao Q; Zheng X; Xu Y; Huang Y; Chen S; Huang Z; Xu H; Jiang K; Zhong Q; Zhang L; Zheng X; Zeng H; Yang S; Li Y; Li S; Zhuang W; Lin G
J Neurooncol; 2023 Nov; 165(2):301-312. PubMed ID: 37995007
[TBL] [Abstract][Full Text] [Related]
6. A Pilot Phase 1 Study of Intrathecal Pemetrexed for Refractory Leptomeningeal Metastases From Non-small-cell Lung Cancer.
Pan Z; Yang G; Cui J; Li W; Li Y; Gao P; Jiang T; Sun Y; Dong L; Song Y; Zhao G
Front Oncol; 2019; 9():838. PubMed ID: 31544065
[No Abstract] [Full Text] [Related]
7. Efficacy and safety of intrathecal pemetrexed for TKI-failed leptomeningeal metastases from EGFR+ NSCLC: an expanded, single-arm, phase II clinical trial.
Fan C; Jiang Z; Teng C; Song X; Li L; Shen W; Jiang Q; Huang D; Lv Y; Du L; Wang G; Hu Y; Man S; Zhang Z; Gao N; Wang F; Shi T; Xin T
ESMO Open; 2024 Apr; 9(4):102384. PubMed ID: 38377785
[TBL] [Abstract][Full Text] [Related]
8. Pemetrexed in the Treatment of Leptomeningeal Metastasis in Patients With EGFR-mutant Lung Cancer.
Choi M; Keam B; Ock CY; Kim M; Kim TM; Kim DW; Heo DS
Clin Lung Cancer; 2019 Jul; 20(4):e442-e451. PubMed ID: 31010639
[TBL] [Abstract][Full Text] [Related]
9. [Clinical characteristics and their influences on the survival of leptomeningeal metastasis derived from lung adenocarcinoma harboring epithelial growth factor receptor mutation].
Jiang AF; Zhou SS; Zhou Q; Zhao J; Li XP; Zhou RR; Li B
Zhonghua Yi Xue Za Zhi; 2023 Sep; 103(34):2713-2719. PubMed ID: 37675543
[No Abstract] [Full Text] [Related]
10. Efficacy and Safety of Intrathecal Pemetrexed Combined With Dexamethasone for Treating Tyrosine Kinase Inhibitor-Failed Leptomeningeal Metastases From EGFR-Mutant NSCLC-a Prospective, Open-Label, Single-Arm Phase 1/2 Clinical Trial (Unique Identifier: ChiCTR1800016615).
Fan C; Zhao Q; Li L; Shen W; Du Y; Teng C; Gao F; Song X; Jiang Q; Huang D; Jin Y; Lv Y; Wei L; Shi T; Zhao X; Gao N; Jiang Z; Xin T
J Thorac Oncol; 2021 Aug; 16(8):1359-1368. PubMed ID: 33989780
[TBL] [Abstract][Full Text] [Related]
11. The clinical characteristic and prognostic factors of leptomeningeal metastasis in patients with non-small-cell lung cancer-a retrospective study from one single cancer institute.
Yan W; Jing W; An N; Tian Y; Guo D; Kong L; Zhu H; Yu J
Cancer Med; 2019 Jun; 8(6):2769-2776. PubMed ID: 30993909
[TBL] [Abstract][Full Text] [Related]
12. Prolonged survival of patients with non-small-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era.
Riess JW; Nagpal S; Iv M; Zeineh M; Gubens MA; Ramchandran K; Neal JW; Wakelee HA
Clin Lung Cancer; 2014 May; 15(3):202-6. PubMed ID: 24524822
[TBL] [Abstract][Full Text] [Related]
13. [Use of Ommaya Reservoirs to Deliver Pemetrexed in Leptomeningeal Metastasis from Non-small Cell Lung Cancer: A Case Report and Review of the Literature].
Lin Y; Li H; Huang M; Guo A; Yin Z
Zhongguo Fei Ai Za Zhi; 2019 Aug; 22(8):546-550. PubMed ID: 31451148
[TBL] [Abstract][Full Text] [Related]
14. Intrathecal pemetrexed combined with involved-field radiotherapy as a first-line intra-CSF therapy for leptomeningeal metastases from solid tumors: a phase I/II study.
Pan Z; Yang G; He H; Cui J; Li W; Yuan T; Chen K; Jiang T; Gao P; Sun Y; Cong X; Li Z; Wang Y; Pang X; Song Y; Zhao G
Ther Adv Med Oncol; 2020; 12():1758835920937953. PubMed ID: 32733606
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era.
Park JH; Kim YJ; Lee JO; Lee KW; Kim JH; Bang SM; Chung JH; Kim JS; Lee JS
Lung Cancer; 2012 Jun; 76(3):387-92. PubMed ID: 22186628
[TBL] [Abstract][Full Text] [Related]
16. Safety, Pharmacokinetic and Clinical Activity of Intrathecal Chemotherapy With Pemetrexed via the Ommaya Reservoir for Leptomeningeal Metastases From Lung Adenocarcinoma: A Prospective Phase I Study.
Li H; Zheng S; Lin Y; Yu T; Xie Y; Jiang C; Liu X; Qian X; Yin Z
Clin Lung Cancer; 2023 Mar; 24(2):e94-e104. PubMed ID: 36588048
[TBL] [Abstract][Full Text] [Related]
17. Concurrent radiotherapy and intrathecal methotrexate for treating leptomeningeal metastasis from solid tumors with adverse prognostic factors: A prospective and single-arm study.
Pan Z; Yang G; He H; Zhao G; Yuan T; Li Y; Shi W; Gao P; Dong L; Li Y
Int J Cancer; 2016 Oct; 139(8):1864-72. PubMed ID: 27243238
[TBL] [Abstract][Full Text] [Related]
18. [Investigation of Methods and Influencing Factors to Increase the Positive Rate of
Cytological Pathology of Cerebrospinal Fluid from Lung Cancer Leptomeningeal Metastases].
Gao N; Teng C; Fan C; Xin T
Zhongguo Fei Ai Za Zhi; 2022 Nov; 25(11):789-796. PubMed ID: 36419392
[TBL] [Abstract][Full Text] [Related]
19. A phase I dose-reduction study of apatinib combined with pemetrexed and carboplatin in untreated EGFR and ALK negative stage IV non-squamous NSCLC.
Huang M; Gong Y; Zhu J; Qin Y; Peng F; Ren L; Ding Z; Liu Y; Cai C; Wang Y; Lu Y
Invest New Drugs; 2020 Apr; 38(2):478-484. PubMed ID: 31231786
[TBL] [Abstract][Full Text] [Related]
20. Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis.
Kuiper JL; Hendriks LE; van der Wekken AJ; de Langen AJ; Bahce I; Thunnissen E; Heideman DA; Berk Y; Buijs EJ; Speel EJ; Krouwels FH; Smit HJ; Groen HJ; Dingemans AM; Smit EF
Lung Cancer; 2015 Sep; 89(3):255-61. PubMed ID: 26117231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
